Quoin Pharmaceuticals, Ltd.

NASDAQ: QNRX · Healthcare · Biotechnology

PublicHQ Ashburn, VA · LoudounCIK 0001671502Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

37D

FH 39DQ 33GM —SS 36

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, filing timeliness · ↓ disclosure history, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$15.8M

Employees

as of 2026-08-22

Market cap

$11.2M

as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02021

Net income-$15.8M-$15.8M2025

Total assets$20.4M$20.4M2025

Liabilities$7.3M$7.3M2025

Equity$13.1M$13.1M2025

Revenue trend

FY2021 – FY2021 · USD

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Quoin Pharmaceuticals, Ltd.’s revenue?

Quoin Pharmaceuticals, Ltd. booked $0 in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Kiora Pharmaceuticals, Inc.52D Izotropic Corporation——United Health Products, Inc.26D Hemostemix Inc——Integrated Cannabis Solutions, Inc.——Theriva Biologics, Inc.39D

Neighbors

Loudoun →

DXC Technology Company$12.6B67B Telos Corporation$164.8M55C Critical Solutions, Inc.——Futuris Company——Reach Messaging Holdings, Inc.——Red Branch Technologies, Inc.$0——

Key facts

CEOMichael Myers

SectorHealthcare

IndustryBiotechnology

HeadquartersAshburn, VA

ExchangeNASDAQ: QNRX

Employees4

IPO date2016-08-01

Latest filings

8-K2026-08-28 8-K2026-08-20 10-Q2026-08-14 8-K2026-08-14 DEF 14A2026-07-16 8-K2026-06-23 8-K2026-06-04 10-Q2026-05-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.